Study: Actos Drug Controls Blood Sugar Levels Better than Avandia
New clinical trial results out of Europe conclude that patients who get a
starting dose of diabetes drug Actos, manufactured by Takeda Pharmaceutical,
have better control of blood sugar and lipid levels than those who take
GlaxoSmithKline's diabetes drug Avandia.
These recent findings were
relayed in a medical meeting in Amsterdam. They will likely bolster Takeda's
contention that Actos (known generically as pioglitazone) is a better drug than
Avandia (known generically as rosiglitazone), which has been linked to heart
attack risks.
The study involved an analysis of data from the first three
months of a six-month head-to-head study of the two drugs.
It found a
starting dose of 30 milligrams of Actos was more effective than a starting dose
of 4 milligrams of Avandia in improving blood sugar levels.
Scientists
presented the research on the two drugs at the annual meeting of the European
Association for the Study of Diabetes.
If you or a loved one has suffered
cardiac complications after ingesting Avandia, you deserve the guidance of a
knowledgeable drug attorney.
Get a free case review by filling out the
form below.
see also:
Senators Testify
Senators Testify in Investigation That FDA Pulled Reviewer off AvandiaAvandia Scientist Says in Investigation that the FDA Removed Him
Another FDA Warning? 10.24.07
New Avandia Setback? Possible Second Black Box Warning on Heart AttackGlaxoSmithKline May Get New Avandia Black Box Warning for Heart Attack
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


